Leerink Partnrs Has Pessimistic View of Geron Q2 Earnings

Geron Co. (NASDAQ:GERN) – Leerink Partnrs lowered their Q2 2025 EPS estimates for Geron in a note issued to investors on Monday, January 6th. Leerink Partnrs analyst F. Khurshid now anticipates that the biopharmaceutical company will post earnings per share of $0.00 for the quarter, down from their prior forecast of $0.01. The consensus estimate for Geron’s current full-year earnings is ($0.25) per share. Leerink Partnrs also issued estimates for Geron’s Q3 2025 earnings at $0.01 EPS and Q4 2025 earnings at $0.02 EPS.

Several other equities analysts have also recently commented on GERN. Barclays upgraded Geron to a “strong-buy” rating in a research note on Friday, November 29th. Needham & Company LLC reiterated a “buy” rating and set a $6.00 price objective on shares of Geron in a research note on Friday, December 13th. Scotiabank assumed coverage on shares of Geron in a research report on Wednesday, October 16th. They issued a “sector outperform” rating and a $6.00 target price for the company. Finally, HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Geron in a research report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $7.15.

Geron Price Performance

Shares of NASDAQ GERN opened at $3.40 on Tuesday. The company has a quick ratio of 2.74, a current ratio of 2.89 and a debt-to-equity ratio of 0.04. Geron has a fifty-two week low of $1.64 and a fifty-two week high of $5.34. The business has a 50 day moving average price of $3.85 and a two-hundred day moving average price of $4.25. The firm has a market cap of $2.06 billion, a PE ratio of -10.63 and a beta of 0.55.

Geron (NASDAQ:GERN) last announced its earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.05. Geron had a negative return on equity of 67.53% and a negative net margin of 682.48%. The company had revenue of $28.27 million during the quarter, compared to the consensus estimate of $18.97 million. During the same period last year, the firm earned ($0.08) earnings per share. The company’s revenue was up 17138.4% on a year-over-year basis.

Institutional Trading of Geron

Institutional investors have recently made changes to their positions in the stock. National Bank of Canada FI raised its holdings in Geron by 1,200.0% during the second quarter. National Bank of Canada FI now owns 6,500 shares of the biopharmaceutical company’s stock worth $28,000 after purchasing an additional 6,000 shares in the last quarter. Readystate Asset Management LP acquired a new position in shares of Geron during the 3rd quarter valued at $58,000. Rovin Capital UT ADV bought a new stake in shares of Geron in the 3rd quarter worth $62,000. CIBC Asset Management Inc lifted its holdings in shares of Geron by 32.7% in the second quarter. CIBC Asset Management Inc now owns 15,438 shares of the biopharmaceutical company’s stock valued at $65,000 after buying an additional 3,805 shares during the period. Finally, Empowered Funds LLC bought a new position in Geron during the third quarter valued at about $67,000. 73.71% of the stock is owned by institutional investors and hedge funds.

About Geron

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis.